Medrx Co., Ltd. (JP:4586)

:4586

4586

Medrx Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥53.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥3.32B

Enterprise Value¥2.40B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-28.53

Shares Outstanding59,365,100

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained gross margins near 85–90% indicate strong unit economics or high product markup. That structural margin buffer gives management room to invest in sales or R&D and improves the probability that the business can reach operating leverage if fixed costs are controlled over the next several quarters.

Conservative Balance Sheet (no Debt)A lack of reported debt reduces solvency and interest-rate risk, giving the company financial flexibility. With no mandatory interest or principal payments, management has more time to restore profitability or raise capital on favorable terms, which is durable support during multi-quarter turnarounds.

Sharp Revenue ReboundA ~186% revenue rebound signals meaningful recovery in demand or successful commercialization progress. If this reflects durable product uptake or contract wins rather than one-offs, it materially improves the base for margin expansion and scale economies over the coming 2–6 months.

Bears Say

Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business does not self-fund operations and will rely on external financing or reserves. Over several quarters this undermines financial flexibility, raises dilution or refinancing risk, and constrains capital allocation to growth initiatives.

Deepening Net LossesAn extreme deterioration of net margin to roughly -732% shows expenses far outstrip revenue despite high gross margins. This structural profitability gap indicates that SG&A, R&D, or other operating costs are unsustainably high and must be addressed for long-term viability.

Negative Returns On EquityPersistently negative ROE demonstrates the company is destroying shareholder capital. Continued losses and cash burn risk eroding the equity base, likely forcing capital raises that dilute shareholders and limit the firm's ability to invest organically in competitive positioning.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥53.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥3.32B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.02 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.02.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥4.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.063%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.